Melanocortin agonism in a social context selectively activates nucleus accumbens in an oxytocin-dependent manner

Neuropharmacology. 2024 Apr 1:247:109848. doi: 10.1016/j.neuropharm.2024.109848. Epub 2024 Jan 20.

Abstract

Social deficits are debilitating features of many psychiatric disorders, including autism. While time-intensive behavioral therapy is moderately effective, there are no pharmacological interventions for social deficits in autism. Many studies have attempted to treat social deficits using the neuropeptide oxytocin for its powerful neuromodulatory abilities and influence on social behaviors and cognition. However, clinical trials utilizing supplementation paradigms in which exogenous oxytocin is chronically administered independent of context have failed. An alternative treatment paradigm suggests pharmacologically activating the endogenous oxytocin system during behavioral therapy to enhance the efficacy of therapy by facilitating social learning. To this end, melanocortin receptor agonists like Melanotan II (MTII), which induces central oxytocin release and accelerates formation of partner preference, a form of social learning, in prairie voles, are promising pharmacological tools. To model pharmacological activation of the endogenous oxytocin system during behavioral therapy, we administered MTII prior to social interactions between male and female voles. We assessed its effect on oxytocin-dependent activity in brain regions subserving social learning using Fos expression as a proxy for neuronal activation. In non-social contexts, MTII only activated hypothalamic paraventricular nucleus, a primary site of oxytocin synthesis. However, during social interactions, MTII selectively increased oxytocin-dependent activation of nucleus accumbens, a site critical for social learning. These results suggest a mechanism for the MTII-induced acceleration of partner preference formation observed in previous studies. Moreover, they are consistent with the hypothesis that pharmacologically activating the endogenous oxytocin system with a melanocortin agonist during behavioral therapy has potential to facilitate social learning.

Keywords: Autism; Basolateral amygdala; Behavioral therapy; Paraventricular nucleus; Pharmacologically enhanced therapy; Social behavior.

MeSH terms

  • Animals
  • Arvicolinae / physiology
  • Female
  • Humans
  • Male
  • Melanocortins / metabolism
  • Nucleus Accumbens* / metabolism
  • Oxytocin* / metabolism
  • Receptors, Oxytocin / metabolism
  • Social Behavior
  • Social Environment

Substances

  • Oxytocin
  • Melanocortins
  • Receptors, Oxytocin